| 2025 | 2024 | 2023 | ||||
|---|---|---|---|---|---|---|
| Gross margin | -869,3 k € | -11991.7% | 7,3 k € | +101.9% | -382,8 k € | |
| EBITDA | -1,6 M € | -232.7% | -487,7 k € | +10.8% | -546,5 k € | |
| Operating profit | -2,6 M € | -30.7% | -2,0 M € | +4.0% | -2,1 M € | |
| Profit/loss | -2,1 M € | -97.6% | -1,1 M € | +4.5% | -1,1 M € | |
| Equity | 1,8 M € | +126.3% | 774,8 k € | -58.1% | 1,8 M € | |
| Total assets | 2,7 M € | +20.3% | 2,2 M € | -10.3% | 2,5 M € | |
| Cash | 1,6 M € | +39.2% | 1,1 M € | -3.1% | 1,2 M € | |
| Debts | 888,5 k € | -37.8% | 1,4 M € | +128.7% | 624,6 k € | |
| Staff | 10,1 | 7,2 | 2,6 | |||
Source: Belgian Official Gazette
Public limited company · Liège · incorporated on 23/05/2022 · 10,1 ETP
Public limited company loss-making in the latest fiscal year. Cash position rising (+39.2%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
THERAtRAME is a Public limited company incorporated in 2022. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 10,1 ETP workers (FTE).